ALTAVOL
LIVE

Serial Number

79395459

Owner

Novartis AG

Attorney

Maury M. Tepper, III

Filing Date

Jan 15, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ALTAVOL Trademark

Serial Number: 79395459 • Registration: 7873757

ALTAVOL is a trademark filed by Novartis AG on January 15, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Novartis AG (12 trademarks)

CH-4002 Basel

Entity Type: 03

Trademark Details

Filing Date

January 15, 2024

Registration Date

July 29, 2025

Published for Opposition

April 29, 2025

Goods & Services

[ Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; ] Medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for the diagnosis and treatment of gastro-intestinal diseases; medical apparatus and instruments for the diagnosis, prevention, and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; medical apparatus and instruments for the diagnosis, prevention, and treatment of hematology diseases and disorders; medical apparatus and instruments for use in tissue and organ transplantation surgery; medical apparatus and instruments for the diagnosis, prevention, and treatment of eye diseases and eye conditions; [ medical apparatus and instruments for the diagnosis, prevention, and treatment of heart rhythm disorders; ] medical apparatus and instruments for the diagnosis, prevention, and treatment of immune system diseases and disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of kidney diseases; [ medical apparatus and instruments for the diagnosis, prevention, and treatment of diabetes; medical apparatus and instruments for the diagnosis, prevention, and treatment of hypertension; ] medical apparatus and instruments for the diagnosis, prevention, and treatment of skin disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of urinary diseases and disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of ophthalmological diseases and disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of cancer and tumors; medical apparatus and instruments for the diagnosis, prevention, and treatment of allergies; medical apparatus and instruments for the diagnosis, prevention, and treatment of bone diseases; medical apparatus and instruments for the diagnosis, prevention, and treatment of respiratory diseases and asthma; radiological apparatus for medical purposes and instruments being radiological apparatus for medical purposes; genetic testing apparatus for medical purposes and instruments being genetic testing apparatus for medical purposes; electromagnetic drug delivery apparatus for medical use and instruments being electromagnetic drug delivery apparatus for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments being medical diagnostic apparatus for testing DNA and RNA samples for medical use; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and instruments being medical apparatus for introducing pharmaceutical preparations into the human body

Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of dermatological diseases; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in the treatment of hematology diseases; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in the treatment of ophthalmology diseases; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 12, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 19, 2026 FICS
FINAL DISPOSITION PROCESSED
Feb 19, 2026 FIMP
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Feb 19, 2026 LIMN
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Dec 2, 2025 NURC
AMENDMENT UNDER SECTION 7 - PROCESSED
Nov 10, 2025 A7OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 3, 2025 APRE
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 29, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 24, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 8, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 8, 2025 OPNR
TEAS SECTION 7 REQUEST RECEIVED
Aug 20, 2025 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 29, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 29, 2025 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jul 9, 2025 ETOP
LIMITATION OF GOODS RECEIVED FROM IB
Jun 13, 2025 LIMG
EXTENSION OF TIME TO OPPOSE RECEIVED
May 15, 2025 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 29, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 29, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 23, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2025 CNSA
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Mar 31, 2025 LOPR
LETTER OF PROTEST EVIDENCE FORWARDED
Mar 31, 2025 LOPT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 10, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 10, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 10, 2025 TROA
REFUSAL PROCESSED BY IB
Jan 17, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 2, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jan 2, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 17, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 16, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 9, 2024 DOCK
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 29, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 29, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 29, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 29, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 29, 2024 COAR
APPLICATION FILING RECEIPT MAILED
May 21, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 21, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
May 15, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 10, 2024 REPR